特朗普与九家药企达成协议 大幅降低药价

Core Points - The agreement between President Trump and nine major pharmaceutical companies aims to significantly reduce drug prices for government Medicaid programs and cash-paying patients [1] - Companies involved in the agreement include Bristol-Myers Squibb, Gilead Sciences, Merck, and Genentech, with Novartis, Amgen, Boehringer Ingelheim, Sanofi, and GlaxoSmithKline also participating [1] - The pharmaceutical companies will lower prices for most drugs sold to low-income Medicaid patients and promise "substantial savings" on widely used medications [1] - Trump has pressured pharmaceutical companies to align U.S. drug prices with those paid by patients in other countries, previously sending letters to 17 major drug company leaders [1] - Five companies have already reached agreements with the government to control drug prices, while three companies—Regeneron, Johnson & Johnson, and AbbVie—have not yet announced agreements [1] - The Director of the Centers for Medicare and Medicaid Services, Mehmet Oz, indicated that these companies will attend the launch ceremony of the government website TrumpRx after the holidays [1]